FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics (Nasdaq:FBLG) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,716,055 covering methods for treating degenerative disc disease using fibroblast conditioned media.

Rhea-AI Summary

FibroBiologics (Nasdaq:FBLG) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,716,055 covering methods for treating degenerative disc disease using fibroblast conditioned media. The patent protects approaches that stimulate fibroblasts with opioid receptor antagonists, such as naltrexone, and toll-like receptor agonists to enhance production of regenerative growth factors like EGF.

Conditioned media and components derived from these stimulated fibroblasts may be delivered directly into intervertebral discs or systemically to promote disc regeneration and stimulate proteoglycan synthesis, potentially offering a less invasive alternative to current pain management and surgical treatments. According to FibroBiologics, this patent expands its intellectual property portfolio within disc degeneration, one of its core clinical pathways, and adds to its 270+ issued and pending patents across multiple disease areas.

Positive

• New U.S. patent issued for fibroblast-conditioned media to treat degenerative disc disease
• Claims cover stimulation of fibroblasts with opioid receptor antagonists and TLR agonists to boost regenerative factors
• Supports core disc degeneration pathway within a portfolio of 270+ issued and pending patents

Negative

• None.

Market reaction after U.S. patent issuance: FBLG +22.67% in the Sep 1 session

+22.67% 7.3x vol

41 alerts

+22.67% Session close to close

+21.5% Peak in 6 hr 59 min

$14.65M Market Cap

7.3x Rel. Volume

In the Sep 1 session, FBLG gained 22.67%, reflecting a significant positive market reaction. Argus tracked a peak move of +21.5% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 7.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +22.7% in the session following this news. FBLG’s 7.98% reaction to the August 20 d...

Analysis

The stock surged +22.7% in the session following this news. FBLG’s 7.98% reaction to the August 20 disc-disease patent announcement provides a directly comparable platform datapoint. The new U.S. patent expands that intellectual-property record, while the active S-3 is a resale registration; clinical validation remains a risk.

Key Figures

U.S. patent number: 12,716,055 Patent portfolio: 270+ patents

2 metrics

U.S. patent number 12,716,055 Treatment of disc degenerative disease

Patent portfolio 270+ patents Issued and pending across clinical pathways

Historical Context

5 past events · Latest: Aug 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 27	Clinical supply update	Positive	+5.7%	Third CYWC628 drug-product batch passed safety and quality testing for ongoing trial support.
Aug 26	Nasdaq compliance	Positive	+0.7%	Nasdaq confirmed FBLG regained compliance with the minimum bid-price requirement.
Aug 24	Board appointment	Neutral	-6.3%	Leigh Steinberg joined the board, but the shares registered a negative 24-hour reaction.
Aug 20	Australian patent	Positive	+8.0%	IP Australia accepted a patent application for cannabidiol-assisted disc-disease therapy.
Aug 18	Preclinical data	Positive	+11.8%	Preclinical study reported cartilage repair within four weeks after one injection.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed four aligned positive reactions to clinical, compliance, and patent news, while one board appointment diverged negatively.

Key Terms

conditioned media, opioid receptor antagonists, toll-like receptor (TLR) agonists, epidermal growth factor (EGF), +2 more

6 terms

conditioned media medical

"Conditioned media and other components derived from these stimulated fibroblasts"

Liquid that has been used to grow or incubate living cells and therefore contains proteins, signaling molecules, metabolites and other substances the cells released; it is collected after cells or tissues have been cultured and is often used as a reagent to study cell behavior or to harvest secreted products. It matters to investors because conditioned media underpins preclinical research, biologic product workflows and assay results, so its composition, consistency and source can affect development timelines, reproducibility and regulatory documentation.

opioid receptor antagonists medical

"cultured with one or more opioid receptor antagonists"

Drugs that bind to opioid receptors in the brain and body but do not activate them, effectively blocking or reversing the effects of opioid chemicals; think of them as putting covers over keyholes so opioid molecules cannot turn the lock. They matter to investors because they are developed as treatments for opioid overdose, addiction management, or to limit side effects of pain drugs, so their clinical progress, approvals and market access can affect company value.

toll-like receptor (TLR) agonists medical

"and toll-like receptor (TLR) agonists"

Toll-like receptor (TLR) agonists are drugs or biological molecules that activate toll-like receptors, a set of immune-system “sensors” that detect danger signals and trigger innate immune responses. They are used to boost or shape immune activity—often as vaccine adjuvants or cancer and antiviral therapies—so their clinical activity, safety profile, and regulatory success matter to investors because they can drive trial outcomes, approvals, and commercial value.

epidermal growth factor (EGF) medical

"including epidermal growth factor (EGF)"

A small signaling protein that binds to the epidermal growth factor receptor on cell surfaces and triggers cell growth, division and survival pathways. It plays a normal role in wound healing and tissue maintenance but is also involved in cancer and other diseases where its signaling can be overactive. Investors encounter EGF when it is mentioned as a drug target, a biomarker, or part of a therapy’s mechanism of action for biotech and pharmaceutical companies.

proteoglycan synthesis medical

"stimulate proteoglycan synthesis"

The cellular process that builds proteoglycans, molecules made of a protein backbone with long sugar chains attached, which help form and maintain the extracellular matrix in tissues like cartilage and connective tissue. Investors care because changes or inhibition in this process are central to many disease mechanisms and are common targets or biomarkers in drug development and diagnostics, so data on proteoglycan synthesis can affect clinical, regulatory, and commercial prospects.

exosomes medical

"components such as exosomes and growth factors"

Exosomes are tiny particles released by cells that carry proteins, genetic material, and other molecules from one cell to another. They act like biological messengers, helping cells communicate and coordinate their activities. For investors, understanding exosomes is important because they are being explored as potential tools for disease diagnosis and treatment, which could influence healthcare markets and innovation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts

HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,716,055, titled "Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibroblast Conditioned Media and Formulations Thereof."

The patent covers methods of promoting disc regeneration by administering fibroblast cells that have been cultured with one or more opioid receptor antagonists and toll-like receptor (TLR) agonists. These compounds, including opioid receptor antagonists such as naltrexone, stimulate fibroblasts to increase the production of regenerative growth factors, including epidermal growth factor (EGF). Conditioned media and other components derived from these stimulated fibroblasts may then be delivered to a patient, either directly into the disc or systemically, to promote disc regeneration and stimulate proteoglycan synthesis.

Degenerative disc disease is a leading cause of chronic back pain and disability worldwide. Intervertebral discs are made of highly organized matrices of collagen, water, and proteoglycans, and with aging, mechanical stress, and other factors, the disc matrix undergoes substantial structural, molecular, and mechanical changes. Current treatment options are largely limited to pain management and invasive surgical procedures, leaving a significant unmet need for therapies that address the underlying degeneration and help restore disc function.

Fibroblasts are the most common cell type found in connective tissue and play a central role in tissue repair. FibroBiologics' patented approach stimulates fibroblasts in culture with opioid receptor antagonists and TLR agonists, prompting the cells to produce elevated levels of regenerative growth factors. The resulting conditioned media, along with components such as exosomes and growth factors derived from it, can be formulated for delivery to degenerated discs with the goal of stimulating proteoglycan synthesis and promoting disc repair without invasive surgery.

"This patent strengthens our growing intellectual property portfolio in disc degeneration, one of our core clinical pathways," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. "By stimulating fibroblasts to produce higher levels of regenerative factors, we believe we can develop treatment options that go beyond managing symptoms and instead work to repair the disc itself."

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.  

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, FibroBiologics' research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-issuance-of-new-us-patent-for-the-treatment-of-degenerative-disc-disease-using-fibroblast-conditioned-media-302865509.html

SOURCE FibroBiologics, Inc.

FAQ

What did FibroBiologics (Nasdaq:FBLG) announce on September 1, 2026 regarding degenerative disc disease?

FibroBiologics announced issuance of U.S. Patent No. 12,716,055 for treating degenerative disc disease using fibroblast conditioned media. According to FibroBiologics, the patent covers methods that promote disc regeneration and proteoglycan synthesis with components derived from specially stimulated fibroblasts.

What does FibroBiologics’ new U.S. Patent No. 12,716,055 cover for FBLG shareholders?

The patent covers methods that stimulate fibroblasts with opioid receptor antagonists and toll-like receptor agonists to produce regenerative growth factors. According to FibroBiologics, conditioned media and derived components can then be delivered to degenerated discs to promote regeneration and stimulate proteoglycan synthesis.

How might FibroBiologics’ fibroblast conditioned media approach differ from current degenerative disc disease treatments?

FibroBiologics’ approach aims to promote disc repair using fibroblast-derived conditioned media rather than focusing only on pain relief or surgery. According to FibroBiologics, this strategy targets regeneration of disc tissue and proteoglycan synthesis, potentially addressing underlying degeneration instead of just symptoms.

How does the new degenerative disc disease patent fit into FibroBiologics’ broader IP portfolio?

The patent strengthens FibroBiologics’ intellectual property in disc degeneration, one of its core clinical pathways. According to FibroBiologics, the company holds more than 270 issued and pending patents across areas including wound healing, multiple sclerosis, orthopedics, psoriasis, human longevity, and cancer.

What role do opioid receptor antagonists like naltrexone play in FibroBiologics’ patented FBLG technology?

Opioid receptor antagonists, including naltrexone, are used to stimulate fibroblasts in culture so they produce higher levels of regenerative growth factors. According to FibroBiologics, these stimulated cells generate conditioned media and components that may support disc regeneration and proteoglycan synthesis.

How is FibroBiologics’ fibroblast conditioned media intended to be delivered for disc degeneration treatment?

Conditioned media and components from stimulated fibroblasts may be administered directly into the disc or systemically. According to FibroBiologics, these formulations are designed to promote disc regeneration and stimulate proteoglycan synthesis, potentially reducing the need for invasive surgical procedures.